Celsion

Founded in 1982, with a vision of using heat to kill cancer and treat other diseases, Celsion began trading publicly in 1985 under the name Cheung Laboratories, Inc. The early research focus of the Company was device oriented heat-based treatment systems. The Company was renamed Celsion Corporation and listed on the American Stock Exchange under the symbol CLN, in the mid 1990's. At that time, Celsion focused its efforts on expanding the Company's research portfolio and licensed technologies for the treatment of Benign Prostatic Hyperplasia (BPH), breast cancer and heat activated drug and gene delivery systems. In 2001, Celsion determined that the greatest potential for long term shareholder value was in the Company's heat activated liposomal drug delivery system and focused its resources on obtaining approval for, commercializing and monetizing its BPH technology. The BPH product has been approved by the FDA and is being marketed as the Prolieve Thermodilatation® system by Celsion's exclusive distributor Boston Scientific Corporation. Under the distribution agreement Boston Scientific has a five year (expiring in February 2009) option to purchase the Prolieve® assets for $60 million. The funds generated to date through the commercialization of Prolieve have been used to develop the company's first drug ThermoDox™ (doxorubicin encapsulated in the company's heat activated liposome) to treat cancer. Celsion is currently engaged in two Phase I dose escalation studies for the treatment of liver cancer and breast cancer patients with loco-regional recurring chest wall cancer.

Contact Details: 10220-L Old Columbia Rd Columbia MD 21046 United States of America Tel: 410.290.5390 Fax: 410.290.5394 Email: celsion@celsion.com WWW: www.celsion.com/

Loading...

Press Releases on Celsion:
Video: Celsion Corporation Initiates Enrollment Awareness Program for Pivotal Phase I/II DIGNITY Trial of ThermoDox(R) in Patients with Recurrent Chest Wall (RCW) Breast Cancer	28th September, 2009	Celsion Corporation	COLUMBIA, Md., Sept. 28 /PRNewswire-FirstCall/ ---- Celsion Corporation (Nasdaq: CLSN) announced today initiation of a nationwide enrollment program in its pivotal Phase I/II DIGNITY clinical trial
Poniard Pharmaceuticals Announces Appointment of Greg Weaver as Chief Financial Officer	19th February, 2009	Poniard Pharmaceuticals, Inc.	SOUTH SAN FRANCISCO, Calif., Feb. 19 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on the development of innovative oncology products,
New appointments prepare Morphochem for cancer product development	1st October, 2003	Morphochem	New appointments prepare Morphochem for cancer product development Munich, Germany, 16 October 2003…Morphochem AG, the transnational
CORRECTED - New appointments prepare Morphochem for cancer product	1st October, 2003	Morphochem	New appointments prepare Morphochem for cancer product development Munich, Germany, 16 October 2003…Morphochem AG, the transnational evolutionary drug discovery and

BioNews Results for Celsion:
Celsion Reports Third Quarter 2009 Financial Results and Business Update	SmartBrief:  Nov 11 2009 12:45AM Matching: celsion
Celsion and Yakult Honsha Announce Treatment of First Patient in Japan in Celsion's Global Phase III ThermoDox	Pharmacy Choice:  Nov 10 2009 12:14PM Matching: celsion
Investigator Meetings Completed in Japan and China for Celsion's Global Phase III ThermoDox(R) Trial for Prima	Pharmacy Choice:  Nov 8 2009 1:17PM Matching: celsion
Celsion to Hold Third Quarter 2009 Financial Results Conference Call Tuesday, November 10, 2009	SmartBrief:  Nov 7 2009 12:07AM Matching: celsion
Celsion and Yakult Honsha Announce Treatment of First Patient in Japan in Celsion's Global Phase III ThermoDox	Pharmacy Choice:  Nov 6 2009 12:11AM Matching: celsion
Promote your company here: BioNewsCast - Press Release Distribution	→View more Celsion news.

Celsion Clinical Trials:
Liposomal Doxorubicin and Thermal Therapy in Treating Patients With Prostate Cancer

Celsion Patents:
US Patent No.	Title
6958075	Device and method for treatment of tissue adjacent a bodily conduit by thermocompression
6807446	Monopole phased array thermotherapy applicator for deep tumor therapy
6788977	System and method for heating the prostate gland to treat and prevent the growth and spread of prostate tumor
6768925	Method for improved safety in externally focused microwave thermotherapy for treating breast cancer
6725095	Thermotherapy method for treatment and prevention of cancer in male and female patients and cosmetic ablation of tissue
→View more Celsion patents.

Celsion (CLN) Financial information Links from Barchart
CLN Quote from from Barchart.com
CLN Chart from from Barchart.com
CLN Profile from from Barchart.com
CLN Opinion from from Barchart.com
→View more Celsion finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 415 times since April 2007, the link to the organisation's website has been followed 69 times

Recent Search Terms used to find this page: renting prolieve system | .

Search for more companies in Columbia

Search for more companies in MD

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Celsion